JNJ (Johnson & Johnson) Moat Score: 9/10 (As of Jul. 01, 2026)


JNJ Johnson & Johnson JNJ
85 GF Score
Price $253.98
GF Value $190.74
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Moat Score?

Johnson & Johnson JNJ 85 Moat Score is 9 as of Jul. 01, 2026. GuruFocus rates JNJ with a GF Score™ of 85/100 and a GF Value™ of $190.74 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Johnson & Johnson ranks better than 99.9% on this metric.

Johnson & Johnson has the Moat Score of 9, which implies that the company might have Wide Moat - Clear and robust wide moat.

Johnson & Johnson has Wide Moat: Johnson & Johnson has a robust wide moat due to its strong brand, extensive intellectual property, significant market leadership, and durable cost advantages. Its diversified product portfolio and global distribution network further enhance its competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Johnson & Johnson might have Wide Moat - Clear and robust wide moat.

Johnson & Johnson  (NYSE:JNJ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Johnson & Johnson Moat Score Related Terms

JNJ vs ABBV, MRK, AMGN: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Johnson & Johnson Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Moat Score distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Moat Score falls into.


JNJ
85GF Score
Johnson & Johnson JNJ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 9 mean?
Johnson & Johnson (JNJ) has a Moat Score of 9 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Johnson & Johnson ranks #1 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Johnson & Johnson's Moat Score too high?
Johnson & Johnson's current Moat Score is 9. Based on the distribution chart, Johnson & Johnson ranks #1 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Johnson & Johnson has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Moat Score compare to ABBV and MRK?
According to the Drug Manufacturers industry distribution chart, Johnson & Johnson ranks #1 out of 1031 companies for Moat Score. This places Johnson & Johnson in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Johnson & Johnson's current Moat Score is 9. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is $190.74, compared to a current price of $253.98 — trading 33.2% above its estimated fair value. The current Moat Score is 9. Johnson & Johnson's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Johnson & Johnson (JNJ), the current Moat Score is 9 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of $253.98 is trading 33.2% above its estimated GF Value™ of $190.74. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for JNJ:

  • Moat Score: 9
  • GF Value™: $190.74 vs. price of $253.98 (33.2% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
85GF Score

Get the complete analysis for JNJ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$253.98
Price
$190.74
GF Value